FY2027 EPS Forecast for Aytu BioPharma Reduced by Analyst

Aytu BioPharma Inc. (NASDAQ:AYTU) – Investment analysts at Ascendiant Capital Markets cut their FY2027 earnings per share estimates for Aytu BioPharma in a research note issued on Wednesday, June 10th. Ascendiant Capital Markets analyst E. Woo now expects that the company will earn $0.25 per share for the year, down from their prior estimate of $0.30. Ascendiant Capital Markets has a “Buy” rating and a $14.50 price objective on the stock. The consensus estimate for Aytu BioPharma’s current full-year earnings is ($0.69) per share. Ascendiant Capital Markets also issued estimates for Aytu BioPharma’s Q4 2027 earnings at $0.16 EPS.

A number of other research analysts also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a report on Wednesday, April 8th. Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aytu BioPharma has a consensus rating of “Hold” and an average price target of $9.83.

Aytu BioPharma Trading Down 2.2%

Aytu BioPharma stock opened at $2.19 on Friday. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. The business’s fifty day simple moving average is $2.40 and its two-hundred day simple moving average is $2.46. Aytu BioPharma has a 12 month low of $1.65 and a 12 month high of $3.07. The company has a market capitalization of $23.50 million, a price-to-earnings ratio of -0.48 and a beta of 0.24.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. The firm had revenue of $12.41 million for the quarter, compared to analysts’ expectations of $12.05 million.

Institutional Trading of Aytu BioPharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its position in Aytu BioPharma by 23.3% in the first quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock worth $119,000 after buying an additional 8,222 shares in the last quarter. Daytona Street Capital LLC purchased a new stake in shares of Aytu BioPharma during the fourth quarter worth about $26,000. Persistent Asset Partners Ltd grew its position in shares of Aytu BioPharma by 27.2% during the fourth quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock worth $206,000 after purchasing an additional 16,963 shares in the last quarter. Rothschild Wealth LLC purchased a new stake in shares of Aytu BioPharma during the fourth quarter worth about $52,000. Finally, Bellevue Asset Management LLC purchased a new stake in shares of Aytu BioPharma during the fourth quarter worth about $65,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.